牛牛AI助理已提取核心訊息
iBio Inc, a biotechnology company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice of an equity offering with the first sale dated 03/26/2024. The filing, signed by CEO Martin Brenner on 04/03/2024, reports a total offering and sold amount of $15,068,745 USD. The offering includes equity, options, warrants, and other rights to acquire securities, with no minimum investment from outside investors. The company has declined to disclose its revenue or aggregate net asset value. Eight investors have already invested in the offering, which is not being made in connection with a business combination transaction. Sales commissions are estimated at $794,124 USD. The proceeds from the offering are proposed to be used as working capital, which may indirectly include payments for salaries to employees, including executive officers. The offering is expected to last no more than one year, and iBio Inc has claimed an exemption under Rule 506(b) of the Securities Act.
iBio Inc, a biotechnology company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice of an equity offering with the first sale dated 03/26/2024. The filing, signed by CEO Martin Brenner on 04/03/2024, reports a total offering and sold amount of $15,068,745 USD. The offering includes equity, options, warrants, and other rights to acquire securities, with no minimum investment from outside investors. The company has declined to disclose its revenue or aggregate net asset value. Eight investors have already invested in the offering, which is not being made in connection with a business combination transaction. Sales commissions are estimated at $794,124 USD. The proceeds from the offering are proposed to be used as working capital, which may indirectly include payments for salaries to employees, including executive officers. The offering is expected to last no more than one year, and iBio Inc has claimed an exemption under Rule 506(b) of the Securities Act.
在特拉華州註冊成立的生物技術公司iBio Inc已向美國證券交易委員會提交了D表格的證券豁免發行通知，表明了新的股票發行通知，首次出售日期爲2024年3月26日。該文件由首席執行官馬丁·布倫納於2024年3月4日簽署，報告總髮行和銷售金額爲15,068,745美元。此次發行包括股權、期權、認股權證和其他收購證券的權利，外部投資者沒有最低投資額。該公司拒絕透露其收入或總淨資產價值。八位投資者已經投資了此次發行，該發行與企業合併交易無關。銷售佣金估計爲794,124美元。本次發行的收益擬用作營運資金，其中可能間接包括向包括執行官在內的員工支付的工資。此次發行預計將持續不超過一年，iBio Inc已根據《證券法》第506（b）條申請豁免。
在特拉華州註冊成立的生物技術公司iBio Inc已向美國證券交易委員會提交了D表格的證券豁免發行通知，表明了新的股票發行通知，首次出售日期爲2024年3月26日。該文件由首席執行官馬丁·布倫納於2024年3月4日簽署，報告總髮行和銷售金額爲15,068,745美元。此次發行包括股權、期權、認股權證和其他收購證券的權利，外部投資者沒有最低投資額。該公司拒絕透露其收入或總淨資產價值。八位投資者已經投資了此次發行，該發行與企業合併交易無關。銷售佣金估計爲794,124美元。本次發行的收益擬用作營運資金，其中可能間接包括向包括執行官在內的員工支付的工資。此次發行預計將持續不超過一年，iBio Inc已根據《證券法》第506（b）條申請豁免。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了